Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incidental Detection of Respiratory Viruses in Lung Transplant Donor-Recipient Pairs: Exploratory Associations With Clinical Outcomes in a Post Hoc Analysis.

Transplant infectious disease : an official journal of the Transplantation Society·2026

Same author

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.

Liver international : official journal of the International Association for the Study of the Liver·2026

Same author

Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia.

Gut·2026

Same author

Modeling Highlights the Challenge of Achieving and Maintaining Hepatitis C Virus Micro-Elimination Among People Who Inject Drugs.

Open forum infectious diseases·2026

Same author

Rat hepatitis E virus infection has multiphasic viral replication kinetics <i>in vivo</i>.

bioRxiv : the preprint server for biology·2026

Same author

Modeling in vitro cell-to-cell spread of hepatitis C viral infection using an agent-based approach.

bioRxiv : the preprint server for biology·2026

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions.

Adquate Mhlanga¹, Louis Shekhtman^1,2, Ashish Goyal¹

¹The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.

|June 12, 2026

Summary

A new model for hepatitis D virus (HDV) treatment with Bulevirtide (BLV) was tested. The model failed to predict real patient outcomes, highlighting the need to include target cell dynamics for accurate treatment predictions.

Keywords:

HDV RNA Monolix bulevirtide mathematical modeling relative standard error

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Experiment Videos

Last Updated: Jun 13, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Area of Science:

Virology
Pharmacometrics
Mathematical Modeling

Background:

Hepatitis D virus (HDV) infection is the most severe form of viral hepatitis.
Bulevirtide (BLV), an entry inhibitor, is approved in Europe for chronic HDV infection.
Existing mathematical models often exclude target cell dynamics, potentially limiting their predictive accuracy.

Purpose of the Study:

To evaluate a two-equation mathematical model (excluding target cell dynamics) against clinical data from HDV patients treated with BLV monotherapy.
To assess the model's ability to predict viral kinetics, treatment duration, and outcomes like viral breakthrough and rebound.

Main Methods:

Non-linear mixed effects modeling (NLME) was used to analyze clinical data from HDV patients treated with BLV.
A published two-equation model was applied to patient data over 96 weeks.
Model predictions were compared against observed non-monophasic viral decline patterns.

Main Results:

The two-equation model failed to reproduce observed non-monophasic HDV decline patterns, including biphasic decline and viral breakthrough.
The model inaccurately predicted treatment duration needed to reach a theoretical cure boundary.
The model could not explain viral rebound after BLV treatment cessation.

Conclusions:

The exclusion of target cell dynamics in mathematical models limits their ability to accurately predict HDV treatment outcomes with BLV.
Incorporating target cell dynamics is crucial for explaining complex viral kinetics, such as non-monophasic decline and viral rebound.
Improved models including target cell dynamics are needed for better prediction of HDV treatment efficacy and duration.